6:05 PM
 | 
Nov 06, 2012
 |  BC Extra  |  Company News

Vivus: 30% of Qsymia prescriptions 'abandoned'

Vivus Inc. (NASDAQ:VVUS) fell $3.13 (21%) to $11.82 on Tuesday after disclosing on a conference call to discuss its 3Q12 earnings that 30% of pending prescriptions for Qsymia phentermine/topiramate are "abandoned by patients due to the cash outlay" for the obesity drug. The company priced once-daily Qsymia at $120-$183.90 per month, depending on the dose. Vivus said payers are covering about one-in-five prescriptions, with an average co-payment of $62. The company said...

Read the full 350 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >